What are the risk factors for developing low‑grade appendiceal mucinous neoplasm (LAMN) and for recurrence or pseudomyxoma peritonei (PMP) in patients with LAMN?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 26, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Risk Factors for Low-Grade Appendiceal Mucinous Neoplasm (LAMN) and Recurrence/Pseudomyxoma Peritonei

Risk Factors for Developing LAMN

The specific risk factors for developing LAMN are largely unknown, as this is a rare tumor typically discovered incidentally after appendectomy. 1 Unlike other gastrointestinal neoplasms where predisposing factors have been well-characterized, the literature does not identify established demographic, genetic, or environmental risk factors that predict who will develop LAMN.

Risk Factors for Recurrence and Pseudomyxoma Peritonei in Patients with LAMN

The most critical risk factors for recurrence and PMP development are tumor stage (particularly T4a and T4b disease), appendiceal perforation, presence of acellular mucin on the serosa, and positive surgical margins. 1

High-Risk Pathologic Features

T Stage:

  • T4a and T4b disease carry the highest recurrence risk, with all patients who developed recurrence in one series having T4a or T4b disease (p<0.001) 1
  • T4b disease (peritoneal involvement) demonstrates particularly aggressive behavior requiring cytoreductive surgery and HIPEC 1
  • Tis (LAMN confined to mucosa) and T3 disease without other risk factors have minimal recurrence risk 1

Appendiceal Perforation:

  • Appendix perforation is strongly associated with PMP development (p<0.001) 1
  • Microscopic perforation/rupture is more frequent in cases that develop PMP compared to those that do not 2
  • Perforation allows mucin and neoplastic epithelium to seed the peritoneum 1

Acellular Mucin on Serosa:

  • Presence of acellular mucin on the serosal surface significantly increases recurrence risk (p=0.004) 1
  • 18 patients with acellular mucin on serosa had 4 recurrences in one series 1
  • Acellular mucin not confined to mucosa but present on serosal surface is more common in PMP cases 2

Tumor Size and Location:

  • LAMN tumor size ≥2 cm is associated with higher recurrence risk (P<0.05) 3
  • LAMNs with limited involvement of the right lower quadrant show increased recurrence risk (P<0.05) 3
  • Patients with either of these two risk factors had 5- and 10-year cumulative recurrence risks of 12% and 30%, respectively 3

Microscopic Features Predicting Higher Risk

Mucin Leakage Indicators:

  • Smaller luminal diameter (<1 cm) with thicker wall suggests luminal mucin leakage 2
  • Separate mucin aggregations indicate mucin has escaped the appendiceal lumen 2
  • These features are more frequent in cases that subsequently develop PMP 2

Neoplastic Epithelium Distribution:

  • Neoplastic epithelium dissecting outward beyond mucosa increases PMP risk 2
  • However, presence of neoplastic cells in muscularis propria alone does not reliably predict PMP 2

Coexisting Diverticulum:

  • Present in approximately 25% of LAMN cases regardless of PMP status 2
  • The diverticular portion represents a weak point where rupture commonly occurs 2

Surgical Margin Status

The relationship between surgical margins and recurrence is complex:

  • Positive margins (involvement of neoplastic cells or acellular mucin) do not necessarily lead to recurrence or PMP 2
  • Clear margins do not absolutely prevent PMP development 2
  • However, positive margins remain a recognized risk factor requiring consideration for additional surgery 1

Overall Recurrence Rates

For appropriately selected low-risk patients, recurrence rates are extremely low:

  • Overall 5- and 10-year cumulative recurrence incidence rates are 3% and 6%, respectively 3
  • Only 1% of patients without the two key risk factors (tumor ≥2 cm or right lower quadrant involvement) developed recurrence at 10 years 3
  • Median time to recurrence is 24 months (IQR 23-87 months) 3

Acellular Mucinosis Prognosis

Patients with purely acellular mucinosis (AM) secondary to LAMN have excellent outcomes:

  • Disease-specific mortality of only 3% 4
  • Recurrence rate of only 3% 4
  • Disease progression in 1.5% 4
  • This represents a distinctly low-risk group compared to epithelial pathology 4

Important Caveats

Rare exceptions exist: Although extremely uncommon, confined LAMN (pTis or pT3) can present with simultaneous extraperitoneal distant metastasis (subcutaneous or ovarian involvement) at diagnosis, despite the primary tumor being limited to the appendix 5. This underscores that even low-stage disease can occasionally behave unpredictably.

References

3
Research

Risk stratification of surveillance for low-grade appendiceal mucinous neoplasms.

Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2024

4
Research

Long-term outcomes for patients with peritoneal acellular mucinosis secondary to low grade appendiceal mucinous neoplasms.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2021

Related Questions

What is the best treatment approach for a patient with a low-grade mucinous appendix after surgery?
What are the typical clinical presentation and demographic features of low‑grade appendiceal mucinous neoplasm (LAMN)?
What is the recommended treatment for a patient with a low-grade mucinous (mucin-producing) neoplasm of the appendix that has metastasized to the ovary?
What actions should be taken if histology results of appendicitis show a low-grade appendiceal neoplasm?
What is a low-grade appendiceal mucinous neoplasm (LAMN)?
When is testosterone replacement therapy appropriate for an adult male with symptoms of hypogonadism and a total testosterone level below 300 ng/dL on two separate morning measurements, assuming no contraindications such as prostate cancer, elevated PSA, untreated sleep apnea, uncontrolled cardiovascular disease, or hematocrit >50%?
When should iron polymaltose injection be reduced or discontinued in patients with renal disease?
In an adult with chronic renal failure, how long can a permanent tunneled cuffed dialysis catheter placed in the external jugular vein be used safely?
What is the recommended management for iron‑deficiency anemia confirmed by low hemoglobin with microcytosis, low ferritin and high total iron‑binding capacity, including first‑line oral iron regimen, indications for intravenous iron, transfusion thresholds, and treatment of the underlying cause?
In a healthy adult with a first unprovoked seizure, when should antiepileptic drug therapy be initiated and which agents are preferred as first‑line treatment?
When should low serum phosphate be treated and how should it be evaluated and managed?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question